Navigation Links
ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China

ROCHESTER, N.Y., YORK, England and BETHESDA, Md., April 1 /PRNewswire-Asia/ -- ACM Global Central Laboratory, the laboratory that continually defines the client-service standard with its inherently flexible approach, and Chindex International, Inc. (Nasdaq: CHDX), today announced a partnership to provide central lab services in China at United Family Hospitals, Beijing (UFH). UFH is a CAP-certified facility owned by Chindex International, Inc.

ACM Global Central Laboratory conducted a harmonization program in China, and chose to work with Chindex in order to ensure the same degree of global standards that clients enjoy from the Americas, Europe, India and Australasia. Offering on-the-ground central lab capabilities in China is a significant milestone in the organization's history.

"Given the challenges of exporting whole blood from Mainland China coupled with the demand for conducting trials in China, we recognized the importance of establishing services locally," said Elena Logan, Vice President, ACM Global Central Laboratory. "We also refuse to compromise on quality and working with Chindex helps us maintain our rigorous service standards in an exciting developing market. I'm honored to be able to work with the UFH team led by US trained pathologist, Dr. Sun Fei, who will oversee the clinical trial efforts at UFH."

"As the only Western-founded hospital lab in Beijing, and the only JCI accredited hospital in China with CAP accreditation, UFH is well-poised to provide unparalleled central lab services. Working with a global leader like ACM acknowledges our unique competitive position as well as our dedication to high standards of care. We also look forward to providing additional diagnostic testing to the local community through this partnership," said Roberta Lipson, CEO of Chindex.

ACM's global operations extend to more than 60 countries, including the Americas, Europe, including Eastern Europe and Russia, Australia, Asia, Israel, South Africa and India - with all tests conducted and managed from central lab facilities with seamless data management providing a single database. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.

"China is an exciting and rapidly growing market for clinical trials and our central lab capabilities there represent an important development for the company," said Tracy Hendershott, Director, Global Operations "Partnering with a qualified lab in China gives us the ideal mix of global standardization combined with local expertise to deliver the best possible service to our clients."

About ACM Global Central Laboratory

ACM Global Central Laboratory has an inherently flexible approach and a focus on precision to keep clinical research studies on schedule. The organization sets itself apart by its single focus on global central lab services. ACM is defining the industry standard by continually developing client-focused processes and services. ACM's global operations extend to more than 60 countries and offer a broad and customized menu of safety and specialty services for clinical trials. The organization performs 13 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including Pathology, Microbiology and Pharmacogenomics. For more information, visit .

About Chindex International, Inc. and United Family Hospitals

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, and .

Safe Harbor Statement

Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2008, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential" or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward- looking statements.

    For further information, please contact:

    Integrated Corporate Relations
     Ashley M. Ammon
     Tel: +1-203-682-8200

SOURCE Chindex International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Aviation Summit Explores Low-Carbon Flight
2. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
3. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
4. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
5. 3rd Global Jatrophaworld Training 2009... Set to Create and Build a Sustainable non-food Biodiesel Industry
6. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
7. Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry
8. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
9. BioMed Realty Trust to Present at Citi 2009 Global Property CEO Conference
10. News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009
11. Abbott to Present at Barclays Global Healthcare Conference
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):